• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Antihypertensives not linked to decreased cardiovascular events: The HOPE-3 trial

byMatthew GrowdonandShaidah Deghan, MSc. MD
May 31, 2016
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 

1. The treatment group receiving a combination of candesartan and hydrochlorothiazide demonstrated significant decreases in systolic and diastolic blood pressure compared to the placebo group.

2. There was no significant difference between the treatment and placebo group in terms of a composite measure of death from cardiovascular causes, nonfatal MI, or nonfatal stroke.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Previous epidemiologic research suggests that there is a graded increase in cardiovascular risk above blood pressures as low as 115mmHg. Prior studies have clearly established the benefits of antihypertensive therapy in patients with systolic blood pressure (sBP) above 160mmHg and an absence of vascular or renal disease, diabetes, or hypertension with end-organ dysfunction. However, less is known about the efficacy of antihypertensive therapy in patients with intermediate risk of cardiovascular disease and sBP under 160mmHg.

The Heart Outcomes Prevention Evaluation (HOPE-3) trial sought to answer this question among 12,705 participants at intermediate risk who did not have cardiovascular disease. These participants were randomized to receive either fixed-dose combination of candesartan and hydrochlorothiazide or placebo. Over a median follow-up of 5.6 years, there were significant and enduring decreases in both sBP and diastolic blood pressure (dBP) in the treatment group compared with placebo. There were no significant differences in terms of primary outcomes (the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke and the composite of these events plus resuscitated cardiac arrest, heart failure, or revascularization).

HOPE-3 adds considerably to the literature regarding antihypertensive use in reducing cardiovascular risk, contradicting the “lower is better” hypothesis. However, the greatest challenge facing practitioners remains synthesizing these findings alongside myriad other studies with conflicting results.

RELATED REPORTS

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

Wellness Check: Mental Health

Click to read the study in NEJM

Relevant Reading: A Randomized Trial of Intensive versus Standard Blood-Pressure Control

In-Depth [randomized controlled trial]: HOPE-3 involved 12,705 participants randomized either to combination of candesartan and hydrochlorothiazide or placebo. These participants had an intermediate risk of cardiovascular outcomes (annual risk of major cardiovascular events of approximately 1%). The population had a mean age of 65.7 years, was 46.2% female, and was ethnically diverse. At baseline, the mean sBP in the entire group was 138.1mmHg; the mean decreases from baseline during the trial were 10.0±13.1 and 4.0±12.9 mmHg in the treatment and placebo groups, respectively. These decreases in blood pressure were consistent with respect to dBP and across time in the trial.

In regards to the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke the two groups did not demonstrate any significant difference across a median follow-up of 5.6 years, with an incidence of 4.1% and 4.4% in the treatment and placebo groups (HR=0.93; 95% [CI], 0.79 to 1.10; p=0.40). In terms of the composite of the aforementioned events plus resuscitated cardiac arrest, heart failure, or revascularization, there was again no significant difference (HR=0.95; 95% [CI], 0.81 to 1.11; p=0.51). In terms of safety, there were significantly higher rates of hypotension, dizziness, and light-headedness among participants receiving treatment compared to placebo.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Rosuvastatin associated with reduction of cardiovascular disease in all ethnicities: The HOPE-3 study

Next Post

Neurocognitive deficits in congenital heart disease may not worsen with age

RelatedReports

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
StudyGraphics

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

May 20, 2022
Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital
Wellness

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

May 20, 2022
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women
Wellness

Wellness Check: Mental Health

May 19, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Next Post
Neurocognitive deficits in congenital heart disease may not worsen with age

Neurocognitive deficits in congenital heart disease may not worsen with age

HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Hospital mobility program linked to preserved mobility following in-patient admission

Selexipag may decrease mortality related to pulmonary arterial hypertension: The GRIPHON study

2 Minute Medicine Rewind May 30, 2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.